"Investigation of the relationship between the recurrence of non-muscle invasive bladder cancer (NMIBC) and intake of the therapeutic agent for dysuria."

"Investigation of the relationship between the recurrence of non-muscle invasive bladder cancer (NMIBC) and intake of the therapeutic agent for dysuria." - "Investigation of the relationship between the recurrence of non-muscle invasive bladder cancer (NMIBC) and intake of the therapeutic agent for dysuria."

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036097

Enrollment

200

Registered

2019-03-07

Start date

2019-03-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The non-muscle invasive bladder cancer (NMIBC)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria were NMIBC (<=T1) and urothelial carcinoma.

Exclusion criteria

Exclusion criteria: The exclusion criteria were the case have past history of primary upper urinary cancer or were the cases with a follow-up period of less than 6 months.

Design outcomes

Primary

Measure	Time frame
EORTC recurrence score and CUETO recurrence score are calculated of each patient, 2nd TUR-BT and BCG therapy, kinds of current or past of medication history of therapeutic agent for dysuria and recurrence status are recorded.	—

Countries

Japan

Contacts

Public ContactYoichiro Kato

Iwate Medical University Urology

katoyooo@iwate-med.ac.jp+81196515111

Outcome results